The New York Times is a recurring publication in the Astral Codex Ten archive, appearing 30 times across 30 issues between January 21, 2021 and November 27, 2024. The archive places it in contexts such as "a very nice and nuanced article about the phenomenon in - of all places - The New York Times"; "all the experts, the CDC, the WHO, the New York Times, et cetera"; "several newspapers, such as The New York Times, produced a few special durable rag-paper editions every day". It most often appears alongside United States, New York Times, Twitter.
- Article page
- The New York Times
- Mention count
- 30
- Issue count
- 30
- First seen
- January 21, 2021
- Last seen
- November 27, 2024
- https://archive.is/iYHJb
- https://en.wikipedia.org/wiki/New_York_(Ukraine)
- https://freddiedeboer.substack.com/p/being-ghosted-by-the-new-york-times
- https://opinionator.blogs.nytimes.com/2015/04/04/do-you-google-your-shrink/
- https://time.com/6301552/weight-loss-drugs-compounding-pharmacies/
- https://www.astralcodexten.com/p/book-review-the-rise-of-christianity
- https://www.astralcodexten.com/p/secrets-of-the-great-families
- https://www.google.com/url?q=https://www.nytimes.com/2023/04/15/nyregion/shoplifting-arrests-nyc.html&sa=D&source=docs&ust=1732585942408331&usg=AOvVaw20ibByzJ-tijOf3155r6lv
- https://www.imdb.com/name/nm10138907/bio?ref_=nm_ov_bio_sm
- https://www.modifynota.org/
- https://www.neonarrative.us/p/an-interview-with-scott-alexander
- https://www.nytimes.com/2018/05/08/opinion/intellectual-dark-web.html
- Still Alive
- WebMD, And The Tragedy Of Legible Expertise
- Your Book Review: Double Fold
- The Rise And Fall Of Online Culture Wars
- Highlights From The Comments On Culture Wars
- Your Book Review: Humankind
- Highlights From The Comments On "Crazy Like Us"
- Adumbrations Of Aducanumab
- Book Review: Modi - A Political Biography
- Highlights From The Comments On Modern Architecture
- Highlights From The Comments On Kids And Climate Change
- Epistemic Minor Leagues
- Your Book Review: Making Nature
- California Gubernatorial Candidates From Z to Z
- In Partial, Grudging Defense Of The Hearing Voices Movement
- Your Book Review: The Dawn Of Everything
- What Caused The 2020 Homicide Spike?
- 22
- Semaglutidonomics
- Sorry, I Still Think I Am Right About The Media Very Rarely Lying
- How Do AIs' Political Opinions Change As They Get Smarter And Better-Trained?
- Links For February 2023
- Book Review: Paper Belt On Fire
- Highlights From The Comments On The Academic Job Market
- Assistant Dictator Book Club: America Against America
- Highlights From The Comments On Social Model Of Disability
- In Defense Of Describable Dating Preferences
- Open Thread 298
- SB 1047: Our Side Of The Story
- Prison And Crime: Much More Than You Wanted To Know
But I still had this really strong sense that my career hung on this thread of staying anonymous. Sure, my security was terrible, and a few trolls and malefactors found my real name online and used it to taunt me. But my attendings and my future employers couldn't just Google my name and find it immediately. Also, my patients couldn't Google my name and find me immediately, which I was increasingly realizing the psychiatric community considered important. Therapists are supposed to be blank slates, available for patients to project their conflicts and fantasies upon. Their distant father, their abusive boyfriend, their whatever. They must not know you as a person. One of my more dedicated professors told me about how he used to have a picture of his children on a shelf in his office. One of his patients asked him whether those were his children. He described suddenly realizing that he had let his desire to show off overcome his duty as a psychiatrist, mumbling a noncommital response lest his patient learn whether he had children or not, taking the picture home with him that night, and never displaying any personal items in his office ever again. That guy was kind of an extreme case, but this is something all psychiatrists think about, and better pychiatrist-bloggers than I have quit once their side gig reached a point where their patients might hear about it. There was even a very nice and nuanced article about the phenomenon in - of all places - The New York Times.
The New York Times thought so. Some people kept me abreast of their private discussions (in Soviet America, newspaper's discussions get leaked to you!) and their reporters had spirited internal debates about whether I really needed anonymity. Sure, I'd gotten some death threats, but everyone gets death threats on the Internet, and I'd provided no proof mine were credible. Sure, I might get SWATted, but realistically that's a really scary fifteen seconds before the cops apologize and go away. Sure, my job was at risk, but I was a well-off person and could probably get another. Also, hadn't I blogged under my real name before? Hadn't I published papers under my real name in ways that a clever person could use to unmask my identity? Hadn't I played fast and loose with every form of opsec other than whether the average patient or employer could Google me in five seconds?
513,000 people read my blog post complaining about the New York Times' attempt to dox me (for comparison, there are 366,000 people in Iceland). So many people cancelled their subscription that the Times' exasperated customer service agents started pre-empting callers with "Is this about that blog thing?" A friend of a friend reports her grandmother in Slovakia heard a story about me on Slovak-language radio.
I can't tell you how many times over the past year all the experts, the CDC, the WHO, the New York Times, et cetera, have said something (or been silent about something in a suggestive way), and then some blogger I trusted said the opposite, and the blogger turned out to be right. I realize this kind of thing is vulnerable to selection bias, but it's been the same couple of bloggers throughout, people who I already trusted and already suspected might be better than the experts in a lot of ways. Zvi Mowshowitz is the first name to come to mind, though there are many others.
Of course, it wasn’t the ideal way. Baker’s frustrated attempts to get America’s chief librarians to explain their discarding policy feel like an endless progression of motte and bailey. The motte is that terminally endangered books need to be microfilmed to preserve their intellectual content; the bailey is that libraries should ditch paper books and switch to microfilm in order to modernize and miniaturize. Baker notes that several newspapers, such as The New York Times, produced a few special durable rag-paper editions every day, specifically for libraries. All for nothing: the libraries ended up ditching these volumes nonetheless. Patricia Battin was the president of the national Commission of Preservation (!) and Access and one of the most ardent supporters of microfilm:
Starting around 2014, Internet feminism went mainstream. This graph doesn't really prove that. Maybe the New York Times just dectupled the amount of space it devoted to sexism for non-Internet-related reasons. But as somebody who lived through this period and watched it closely - no, it was the Internet. The blogs and forums of the early 2010s were a memetic breeding ground that produced new and more compelling versions of old ideas, and one of them took over liberal culture.
The first milestone on that path was Milo Yiannopoulos. As outrageous and offensive as he was, he was actually a step above everyone who had come before him in terms of visibility and respectability - at least nobody expected him to shoot up a school or anything. The second milestone was Jordan Peterson, who was an obvious step up in respectability beyond Milo. There was a really interesting period in 2016 when the media was trying to decide whether to unite in character-assassinating Peterson the same way it had character-assassinated all previous people in this space, or treat him as some sort of interesting and potentially sympathetic phenomenon, and it decided on the interesting phenomenon angle. After that, being anti-SJW lost about 90% of its stigma, to the point where people would roll their eyes instead of freaking out. This New York Times article on the Intellectual Dark Web essentially turned the semi-respectability of anti-SJWism into common knowledge, and makes a fascinating contrast with the TIME article on MRAs linked above.
Second, while I agree that Doritos isn’t going to invent special flavors to celebrate May Day, most of the portrayals I’ve seen of socialism in media and academia have been broadly positive. They haven’t been quite as fawning to socialists as to woke people, but overall the effect still seems pro- rather than anti-; articles like this one seem more the rule than the exception. Even when the mainstream says something mildly negative about socialism, like here, nobody would confuse it for something they’re actually against, like the border wall or something. If this is the best that the powers-that-be can do in terms of class warfare to defend their position, it’s pretty pathetic.
Culturally, the anti-elite movement does seem to be regaining steam -- that, or the progressives are losing theirs. The most intellectually satisfying thing I've seen on the internet in the last year was Niccolo Saldo's gonzo interview with Anna Khachiyan. Curtis Yarvin might have been the best writer in the last couple years. I don't take the policy ideas of either of these authors seriously and neither do they -- which is itself a political idea, perhaps one of their best. Almost every mainstream media outlet, while diligently policing the opinions of Twitter randos with 5 followers, can't help methodically destroying progressive holy cows in articles that end up among their most shared ( https://www.nytimes.com/2021/02/24/us/smith-college-race.html , https://www.theatlantic.com/politics/archive/2021/05/liberals-covid-19-science-denial-lockdown/618780/ just to mention the first two that came to my mind). Hard to argue with click rates, it seems. This all doesn't compare remotely to the cultural explosion of the 60s, but is anything moving at all on the other side?
Don't trust any study which hasn't been replicated Why you shouldn't stand by the bystander effect In 1964 at 3:19am Catherine Genovese was attacked in front of 38 witnesses in a nice neighbourhood in New York. For half an hour none of them did anything to help, allowing her attacker to strike again. Finally at 3:50am one calls it in. The police arrive two minutes later, but it's too late for Kitty. This phenomenon is called the bystander effect. In an experiment where subjects hear someone in trouble they rush to help, but if they know 5 other subjects are also listening in only 62% of them do - it's someone else's problem. If Kitty had awakened only one person she might still be alive. Except that once again I've told you how Kitty Genovse's murder was reported, not what actually happened. Let's try again. At 3:19am Kitty's scream rings out. There aren't 38 people who hear it - it's cold, they have their windows shut, and they're asleep. 38 is the number of people the police interviewed afterwards, most of whom did not witness anything. Of those who do wake up and look out they see a woman lurching down the street, apparently drunk. Nonetheless two of them immediately call the police, who have other drunk people to deal with, and decide this isn't very important. Two people witnessed the actual attack. One did indeed do nothing. The other was scared of being picked up by the police for being drunk and homosexual in a built-up area (this was 1964), so he told a neighbour, who immediately rushed down to Kitty, heedless of the danger. Five days later Kitty's murderer was caught after a bystander noticed a man carrying a TV set out of a neighbour's house. He and a friend called the police, and disabled the man's car. And the bystander effect itself? It's real, and it replicates, for the sort of low jeopardy situations you can get an ethics committee to sign off on, but what about violent situations like Kitty's? They were unstudiable until Marie Lindegaard had the bright idea of using CCTV footage of real incidents to evaluate bystander behaviour in violent situations. In these high stakes situations bystanders intervene 9 times out of 10, with the rate of intervention rising if there are more bystanders. In the studies bystanders were prevented from interacting, but in real life where they can communicate bystanders exhibit spontaneous team work. I guess I need to add 'don't trust the New York Times' to my list of lessons learned (apparently they sometimes threaten to do other bad stuff as well). Part 3: Against Empathy, God and Civilisation Empathy is too narrow The German infantry of WWII was perhaps the most impressive in history. Martin Van Creveld has calculated that the average German solider inflicted 50% more causalities than his allied counterpart. The Italians in Africa hated them, yet admitted they would have been crushed by the British if not for them. When the Soviets were rolling up their eastern frontier, and allied armies had successfully landed across France it was pretty clear that Germany was toast, but they fought on with astonishing tenacity, and a shockingly low desertion rate. Trying to figure out how to break the German morale, allied psychologists interviewed German POWs. Were they motivated by patriotism? A belief in Nazism? A mistaken belief that this war could still be won? An indoctrinated hatred of Jews? No, the secret was friendship. The Germans had a tremendous 'marital ethos', placing a high value on loyalty, camaraderie and self-sacrifice. Ideology was present, but entirely secondary. Bregman speculates that the German army was better because the friendships of its soldiers were stronger, but admits this is only speculation: interviews of British and American soldiers produced the same results. His key point is that empathy - such as feeling for your fellow soldier - can be a force for evil rather than good, because we can't be empathetic for all humans, only for ones we 'see'. He quotes Professor Paul Bloom who has written a book. "It's about empathy," he says. "I'm against it." (The book is subtly titled Against Empathy). Experiments on babies and toddlers show that they are generally eager to help, but easily manipulated. There's an experiment that shows babies two puppets, one being helpful and the other being mean. After the show all the babies want the helpful one, but show the mean puppet sharing their preference between crackers and green beans, and suddenly they'll take that one over one that was helpful but different from them. Adults are not beyond a bit of empathy manipulation either. People were told the sad story of Sheri Summers, a 10 year in need of a transplant. Would they bump her up the list, ahead of other people whom they knew nothing about, but the doctors who ordered the list believed were better candidates? No, on the whole they wouldn't. Then they took another group given the same scenario, but with the additional instruction to imagine how she felt. Suddenly the majority were up for throwing justice and rationality to the wind (it'd be nice to check whether the effect moved from just below half to just above, but the paper is behind a paywall). Power kills empathy 500 years ago Machiavelli literally wrote the book on how to use immoral means to maintain power. Today this approach is called 'realism', reflecting the confusion between real and cynical with which Humankind began. The Prince has maintained its fame ever since, but being old and famous are no guarantees of being correct, see for example Aristotle on physics, race or women (but don't fall into the trap of thinking Aristotle was wrong about everything - that man was prolific). When Professor Dacher Kelter started working on the psychology of power in the 90s he noticed two things: Everyone assumed Machiavelli was right
https://www.nytimes.com/2017/10/16/science/depressed-fish.html
A new program in 1992 allowed for “accelerated approval” on the basis of surrogate markers, which are indirect measures of a drug’s benefit, assessed via laboratory or imaging tests, that stand in for more meaningful outcomes such as life expectancy. But the implementation of these accelerated processes was criticized by some scientists and patients, even at the time. In 1994, for example, The New York Times cited skeptics who worried that “no one can tell if the drugs work.” Eight months later, the AIDS activist organization ACT UP San Francisco called Anthony Fauci a “pill-pushing pimp” for supporting CD4 immune-cell counts and viral loads as surrogate markers. They were completely invalid, the activists wrote, and nothing more than “a marketing exec’s wet dream.”
A group called the Association of Public Health Laboratories literally begged the FDA to be allowed to deploy the COVID tests they had sitting on the shelf ready for use. The head of the APHL went to the head of the FDA and begged him, in what they described as “an extraordinary and rare request”, to be allowed to test for the coronavirus. The FDA head just wrote back saying that “false diagnostic test results can lead to significant adverse public health consequences”.
There were so, so many chances to avert this. NYT did a great article on Dr. Helen Chu, a doctor in Seattle who was running a study on flu prevalence back in February 2020, when nobody thought the coronavirus was in the US. She realized that she could test her flu samples for coronavirus, did it, and sure enough discovered that COVID had reached the US. The FDA sprung into action, awarded her a medal for her initiative, and - haha, no, they shut her down because they hadn’t approved her lab for coronavirus testing. She was trying to hand them a test-and-trace program all ready to go on a silver platter, they shut her down, and we had no idea whether/how/where the coronavirus was spreading on the US West Coast for several more weeks.
The New York Times quoted figures issued by the National Sample Survey Office [that] showed poverty levels for Muslims in Gujarat at 39.4% in 1999-2000 and still 37.6% in 2009-2010...for Gujarat's Muslims not to have improved their fortunes at all - to have experienced by comparison a catastrophic decline as overall poverty in Gujarat fell by 47.8%...was surely a searing indictment of Modi's policies.
In fact, the NSSO had already released a newer set of data for 2011-2012 that showed the number of Gujarati Muslims below the official poverty line at only 11.4% compared with a national average of 25.5%. This was the fifth best performance by a state in India...this proved exactly the opposite of the point made by the New York Times...so why had nobody else noticed, and why was the 2009-2010 figure being taken at face value? [...]
I'm not a far-right demagogue and I don't want to be a head of government. But I did manage to piss off the New York Times last year, and they wrote a retaliatory hit piece against me. It accused me of being racist, sexist, elitist, all kinds of negative things. There was nothing about it that even hinted I was an acceptable person in any way. Here's what happened to my email subscriber numbers after the piece was published:
Left: the dreaded McMansion, widely reviled as an eyesore ruining the built environment. Right: a house designed by Valerio Ogliati, an a world-famous architect profiled by the New York Times last month. Michael Watts brings up an aspect of signaling I’d forgotten about:
- The representational art of Western Europe, starting with Constantine, and throughout the Middle Ages (with the exception of the Frankish court and some Byzantine art), up until nearly 1300 AD, seems to have been very deliberately bad, and in many times and places it was banned entirely. This was probably due to Christianity and Islam both having a horror of the misleading power of representational art (which fear came straight out of Plato). Note much medieval art was also Cubist.
This also reminded me of the recent Ezra Klein piece on David Shor. Shor is telling Democrats that if they took more popular positions they could get more votes; Democrats’ response has been mixed:
I've also always questioned how flights play into this, even though the share of emissions is relatively small. Rural residents do drive much more, but rarely fly. Half the US never flies. Based on my anecdotal experiences in NYC and DC it seems likely that they account for an outsize share of these emissions as well, although I can't find data on this beyond broad emissions stats - https://www.nytimes.com/interactive/2019/10/17/climate/flying-shame-emissions.html
But it would have been even better if he'd gone meta and noticed that he himself is being motivated by the discovery drive. He claims to have found a secret resonance - one between QAnon and alternate reality games (for best effect, imagine him having a conspiracy corkboard and pinning red string between pins marked QANON and ARGS). Then he contributes it to a shared community of knowledge-seekers. The community of people who read blog posts to try to understand QAnon is vast, and Hon's post quickly became a classic that got profiled in Wired and The New York Times, and inspired countless further works of analysis (including this one).
First page of the first edition of Nature, 4 November 1869 II. One Hundred Years of Building a Reputation Despite its popularity, Nature didn’t become prestigious overnight. Far from it, in fact. Making Nature often reminds us that the journal spent most of its history as a low-grade publication where anything could be printed quickly, as long as it was factually correct. (This was ensured by basic checks from the editorial team; Nature articles were not consistently peer-reviewed until the 1970s.) As late as the 1960s, a researcher publishing a preliminary report in Nature was expected to follow up with a longer paper “in a more serious journal.” In other words, Nature delivered quick and cheap distribution, not luxury brand approval. This changed about fifty years ago, as we’ll see in Part III. But to understand what happened then, we first need to examine the characteristics of the journal in the roughly 100-year period from its early days until prestige took over, starting with a deeper look into publication speed. Publication Speed John Maddox, editor of Nature in the late 20th century, said that “one of Nature’s greatest early assets was the speed of the Royal Mail.” You could write to Nature, be published within a week, and read the replies to your communication within two weeks. This was state-of-the-art communication tech! Consider how many times publication speed is mentioned throughout the first half of the book (emphasis mine): What made Nature unique was, in large part, its ability to act as a venue for . . . discussions via its correspondence columns and its weekly publication schedule. (p. 8) Many British men of science found that one of the fastest ways to bring a scientific issue or idea to their fellow researchers’ attention was to send a communication to Nature. (p. 39) Unlike the literary periodicals, there was almost no delay between the submission of a piece and its appearance in the journal. (p. 63) A second reason Nature’s speed of publication would have been compelling to men of science is that getting one’s work into print quickly had become an increasingly essential part of establishing priority for a scientific finding or theory. (p. 65) Scientific weeklies [such as Nature] played a unique role in researchers’ publishing strategies at the end of the nineteenth century by offering researchers a forum where short articles could be printed quickly. (p. 105) Both the Proceedings [of the Royal Society of London] and the Philosophical Magazine had significant lag times between submission and publication . . ., which made Nature and its weekly turnaround uniquely valuable for the priority-conscious Rutherford. (p. 109) [Rutherford] sent his most interesting experimental results [to Nature] immediately, both as a way of keeping his colleagues updated on his work and as insurance against being scooped as he had in 1899. (p. 112) These quotes highlight two distinct reasons why speed was important. The first, as I hinted at earlier, was Nature’s role as the аcademic social media of its time. It was simply the best way to have discussions about scientific topics — or science itself — that could, unlike private correspondence, reach a large audience. More on this in the next section. The second reason, as shown by the mentions of physicist Ernest Rutherford, was establishing priority. Today we take for granted that being the first to publish new ideas or results is important, but in the 19th century this was less clear. To bring up Darwin as an example again, he kept his thoughts on evolution private for many years, because he wanted to make sure his argument was sound before he submitted it to the public (although he did eventually sense the urgency of publishing the theory before Alfred Russel Wallace did). But as science became professionalized, “not being scooped” became more and more crucial, and the weekly Nature was a good tool to avoid that. All this talk of speed may surprise anyone who has recently submitted a paper to Nature. In 2016, an analysis revealed that the median time for Nature to review a paper was 150 days, i.e. 5 months, up from 85 days a decade earlier. Nature itself reports, for the year 2020, a median time of 226 days between submission and acceptance. We’re a long way from “less than a week.” Why was there a decrease in publication speed? As we might expect, the reason was Nature’s growing popularity, especially among the international scientific community. At least, that’s what happened the first time there was a slowdown, in the mid-20th century. Early on, Nature was a journal for and by British scientists. But in the first half of the 20th century, science in general and Nature in particular began to involve much more collaboration between researchers across borders. It was a big deal, for instance, when a foreign government banned Nature, as Nazi Germany did in 1938; German researchers had been using it as an important source of scientific news. The ban was furthermore covered in non-British media, such as The New York Times, indicating that the journal was internationally newsworthy. Such an increase in international readership meant more letters and articles sent to the editors, and by the 1950s, there was such a backlog that submissions needed to be held for six months or more. In the 1960s, the new editor John Maddox recognized this as a problem. He began his editorship by clearing the backlog, and even printed the date of submission along with each scientific paper to show everyone how quick Nature was at reviewing articles (“often within a month,” Baldwin’s book says). Clearly, Maddox thought that restoring the speedy reputation of the journal was important. He seems to have succeeded, for a time. As late as 1989, during a controversy around cold fusion, a Wall Street Journal article said that Nature was still fast: it was able to print papers “in as little as three weeks instead of the more usual lead time of six to twelve months for other scientific publications.” Thus, despite a dip in the middle of the century due to its popularity and international reach, speedy publication was still an important characteristic of Nature in the 1970s. A second — and so far permanent — decrease occurred more recently, perhaps as a result of prestige and the competition of near-instantaneous online platforms, but that’s another story. Network Effects As of 2022, scientists argue in public on Twitter, blogs, and other online platforms, like ResearchHub. In the 19th century, Twitter and ResearchHub hadn’t been invented [citation needed]. Fortunately, Nature was there. A network effect occurs when the value of a product comes primarily from the people who use it. If there are two competing telephone systems, the most valuable one is whichever has the most users (or at least the users you want to talk to). If you create an improved Twitter clone, then all its amazing features won’t do much if you don’t somehow manage to capture Twitter’s network of several million people. Likewise, Nature became an interesting journal to read and contribute to because it gained the attention of Britain’s scientific elite as the place to discuss big science questions. This role as a forum was a constant in Nature’s history, as Making Nature shows with several detailed accounts of debates that took place within the journal’s pages. Some examples: Controversies over the age of the Earth in the 1880s.
A central point of Making Nature is that Nature co-evolved with the British and international institutions of science. To do so, it had to strike a balance between conservatism and innovation. My impression is that Nature was more often on the conservative end of the spectrum, serving as a rock-solid stage where the rest of science could take place. Such an attitude was helpful from the beginning, but it probably became even more important after the 1970s, when everything changed. III. WTF Happened in the 1970s? A fun puzzle from the social sciences: what happened in the early seventies? As evidenced from a multitude of charts, various patterns in society seem to have veered off course around 1971, including growth in wages, inflation, housing costs, energy consumption, number of lawyers, divorce rates, fertility rates, and meat consumption. Whether it was a coincidence or part of the same mysterious phenomenon, we can add to this list the rise of prestige in the science publishing industry. To be clear, I’m the one who claims that this shift was a specific and momentous event. Melinda Baldwin acknowledges many times that Nature went from a low-grade magazine to a prestigious journal, but she remains vague as to what, exactly, was the turning point. In the chapter on the 1970s, she treats the increased selectivity and reputation as just one of many things that happened during this period. It was only in the course of writing this review — with a deliberate focus on prestige — that I realized something significant had occurred in that decade, and that this something affected more than just Nature. Let’s see what the book does tell us, and then I’ll offer a plausible explanation from elsewhere. Changes to Nature in the 1970s The 1970s mostly coincide with the leadership of Nature’s shortest-tenured editor, David Davies. Davies took over from John Maddox in 1973 and proceeded to make a number of changes. He made Nature a unitary publication again, after a short-lived experiment to split it into three journals. He reformed the style guide for contributors. He allowed for cartoons and some humor in his editorials. He also overhauled the journal’s physical appearance: from now on, Nature’s covers would feature interesting images as opposed to articles or advertisements. Today’s covers are still in that tradition. Here’s the Nature cover from 2016, as used on the Wikipedia page of the journal. Nature under Maddox and Davies followed the same trend of internationalization as in the previous decades, but the seventies saw what was perhaps the fastest growth outside the UK. Consider these approximate statistics on the origin of research articles from the years when there was a change in editorship: 1966 (when Maddox became editor): 40% British and 60% international
The latest step in his intellectual evolution is his book San Fransicko: Why Progressives Ruin Cities, which points out all the rampant crime and drug use and homelessness and garbage in SF and says maybe some of these things are bad (the New York Times wrote a negative review here).
Still, I think of these candidates the same way Ross Douthat thinks about cults. They themselves may be crazy and of questionable value. But they’re the extreme version of a healthy tendency. They’re a live canary singing happily in the coal mine, demonstrating that something good still exists in American culture. Some people are still hopeful, entrepreneurial, free-thinking, and invested in democracy.
The New York Times has an article out on the Hearing Voices Movement - ie people with hallucinations and delusions who want this to be treated as normal and okay rather than medicalized. Freddie deBoer has a pretty passionate response here. Other people have differently passionate responses:
I’ve met some Hearing Voices members. My impression is that everyone on every side of this discussion is a good person trying to make the best of a bad situation (except of course New York Times journalists, who are evil people destroying America). Some specific thoughts:
People hate admitting that some cases are mild, and others are severe. Especially the kind of people who work at the New York Times
Enter The Dawn of Everything, which tries to change the past by taking a third way orthogonal to the Rousseau/Hobbes spectrum. Published to widespread acclaim just six months ago, it was blurbed by the likes of Noam Chomsky and Nassim Taleb, and given glowing reviews in The New York Times, The New Yorker, and many others. A doorstopping tome of public-facing but dense scholarship, it harkens back to back to an older age—it even has overwrought Victorian section titles calligraphed in ALL CAPS.
And after a year or two, the pattern became clearer, and now even the detractors don’t seem to really have their heart in it anymore. The New York Times had an article Deconstructing The Ferguson Effect, subtitled “The idea that the police have retreated under siege will not go away. But even if it's true, is it necessarily bad?”, which as far as I can tell is as close as the New York Times has ever come to acknowledging that a politically inconvenient fact is true.
This is basically par for the course. Read New York Times’ or Washington Post’s The Atlantic’s or Pew’s or Voice of America’s articles on this same topic. They’re all exactly the same “It’s a complex combination of factors, we can never know for sure, but probably the pandemic is the most important thing”.
I won’t waste your time by speculating on why they might do this, or what the implications might be for the truth of everything else you read on these sites. I have tried this so many times and it never works. People keep saying things like “oh, I liked when he made an compelling statistical case showing that the media was completely wrong on this one thing they sounded very confident in, but then he started saying the media is often wrong and biased, and that sounded cliched and conspiracy-ish and right-wing, so I lost interest”.
The immediate cause of the July 1 spike could have been this New York Times article, saying Trump was getting close to announcing his candidacy. So you could make an argument that the decline from 6/19 to 6/29 was a genuine effect of damaging insurrection revelations, and then the spike around 7/1 was an unrelated boost from people increasing their probability that he would run. If true, that suggests that P(Trump wins|Trump runs) is pretty high, since even small revelations about his intentions move the market a lot.
One of the Congressmen even has the last name “Kind!” Some pharma lobbyist probably got a bonus for that one. Private insurers mostly have to cover whatever Medicare does, but they can choose whether or not to include extra non-Medicare-covered drugs. Some have chosen to cover semaglutide under some conditions. Others would prefer not to cover it, but can be scared into covering it by the magic words “medical necessity”. Overall I don’t understand the laws here beyond that maybe they’ll cover it and maybe they won’t. Here, too, it might be time for change. The New York Times is publishing articles trying to convince us that private insurances not covering semaglutide is an outrage. Here in the tiny gray text, I want to take a second to complain about this article. It notes that Wegovy (semaglutide for obesity) costs more per prescription than Ozempic (semaglutide for diabetes), and calls this “a gross inequity”, accusing Novo Nordisk of “charg[ing] people more for the same drug because of their obesity”. But the obesity prescription is higher dose than the diabetes prescription! Milligram per milligram, Wegovy costs *less* than Ozempic! A steelmanned version of the NYT might object - don’t most of the costs come from the intellectual property and not the manufacturing, so that dose shouldn’t matter? Yes, but if you made the obesity version cost too much less per milligram than the diabetes version, then diabetics would cheat the system by buying the obesity version and splitting it into smaller doses! Insurances that do cover it may require extra documentation that the patient has tried lots of diet and exercise, maybe including some official diet-and-exercise program like WeightWatchers. They might also want documentation that patients have tried cheaper earlier-generation weight loss drugs without success. Even when insurances do cover semaglutide, copays may be very high. I have a pretty minimal insurance and it looks like if I got semaglutide my copay would be about $500/month until I reach my out of pocket limit. Harsh. People with better insurances might get hit less hard, but I don’t think anyone will be picking this up for cheap. Let’s say only 5% of people who clear all previous hurdles can afford the drug. How Many People Get Semaglutide? 140 million obese Americans * 25% interested * 5% know of semaglutide’s existence * 37.5% can get prescriptions * 5% can afford it = 33,000, which is a pretty good match for the 50,000 estimated prescriptions. I didn’t even fudge the numbers to come out right, it just happened. The Coming Decade As a service to pharma investors, Morgan Stanley modeled the economic future of obesity medications over the next decade. Their headline result: semaglutide and various semaglutide-copycat-drugs will be a $30 billion market by 2030. That’s less than the $500 billion disaster I was afraid of! But still almost 10% of all US drug spending! Here are two core analyses from the report: The first analysis asks “what if doctors medicalized obesity as comprehensively as they’ve medicalized hypertension and high cholesterol?” That is: what if we put in a society-wide effort to get every obese person to a doctor, and after only a little diet and exercise, the doctor puts them on a medication? They find that the US obesity market would multiply by a factor of 25, to about $87 billion/year. The second analysis is a more realistic projection for the next decade. Two things stand out. First, the number of patients on Wegovy or related medications goes from an estimated 46,910 now (pretty close to my 50,000 estimate!) to 11.3 million in 2030. Second, the cost per prescription goes from $15,000/year to about $4,000 year. Let’s look at this second change in more detail. Right now semaglutide is literally in a class of its own for weight loss. But remember, it started as a GLP-1 agonist diabetes drug. And there are other GLP-1 agonists already in use for diabetes. Novo Nordisk’s competitor Eli Lilly owns a closely related molecule, tirzepatide (Mounjaro®). They’ve already done studies showing it also works very well for weight loss - if anything even better than semaglutide - and they’re expected to get FDA approval to market it as a weight loss medication next year. Although capitalism fans might expect the presence of two competing drugs to immediately drive down prices, this is mysteriously not how things work in health care and prices will probably stay the same in the short term. But several other companies are working on semaglutide-like drugs, some will be cheaper to produce than semaglutide, and Morgan Stanley expects that this stronger level of competition will eventually drive costs down to $350/month ($4,000/year) by 2030. “Mounjaro” sounds like the playful animal sidekick in a Disney movie. From a purely economic perspective, semaglutide costs the health system money (because it’s expensive) but also saves the health system money (because we don’t have to pay for obesity consequences like diabetes and heart attacks). Which effect wins out? According to the Institute for Clinical and Economic Review, benefits would outweigh costs if semaglutide cost less than about $8,000/year. Since it costs $15,000 year now, it’s not cost effective. But if Morgan Stanley’s model comes true and it costs $4,000/year in 2030, then it will be cost effective. So at some point, Medicare (and so insurance companies) may start covering it more out of self-interest. I can’t tell whether the model takes this into account or not. (there’s also a third-level effect where it costs the health system money again, because it prevents people from dying of obesity-related complications, and dead people stop needing expensive health care. I think health economists are supposed to ignore this level.) 11.3 million prescriptions at $4,000/year comes to $45 billion, but Morgan Stanley expects that not everyone will fill their prescriptions consistently or stay on the medication the same amount of time, leading to their $31 billion figure. Towards The Glorious Post-Obesity Transhuman Future The Morgan Stanley report shows that even the greediest pharma investors, openly plotting to medicalize obesity, can’t bring themselves to believe in more than 11 million US semaglutide patients by 2030. That’s less than 10% of the US obese population. Isn’t that kind of disappointing? We’ve got > 100 million people dealing with a condition that not only makes them unhealthy, but also causes them psychological distress, and makes lots of people low-grade disappointed in and repulsed by our society. And we’ve got an effective drug that treats the condition. And we’re going to use it on less than 10% of the people involved? In 2032, semaglutide goes off-patent. It will probably take a few years to sort out legal issues and ramp up generic production, but by the mid-2030s, its price will go way down. I don’t think there are technical barriers to getting it down as low as $10 - $100 per month. By then, maybe there will be even more exciting branded weight loss drugs for wealthy people to choose from. But at the very least, semaglutide itself should become much more widely available even to poor or uninsured patients. I’m not sure what will happen. Will there be an inflection point, where so many people use semaglutide that obesity becomes unusual again, and then the remaining obese people start using it just to fit in? Will obesity become an optional fashion statement, like shaving your head or getting a tattoo? Or will semaglutide end up disappointing us in some way, like so many promising drugs have before? I come at semaglutide from a transhumanist perspective. I want to hack genetics and biology until everyone is as tall as they want, as strong as they want, as smart as they want, and whatever gender they want. If you want wings, you should be able to have wings. And yes, part of this vision is everyone having the weight they want. I’m not sure this will happen, but for the first time I can see a clear path to how it might. Postscript 1: Should You Take Semaglutide? I can’t answer this, please ask your doctor. But I do want to add that there are potential side effects I haven’t mentioned in this post, including nausea, gastrointestinal problems, pancreatitis, and kidney problems. Semaglutide has been accused of slightly increasing risk of pancreatic and thyroid cancers. Studies have found trends in this direction, but these conditions are so rare that even over thousands of patients over many years, the increase hasn’t yet reached clear statistical significance. The current consensus position is that it may increase thyroid cancer by a tiny amount not relevant to most patients, and that it probably doesn’t increase pancreatic cancer. I think my father has looked over these data more and is less sure than other people about the lack of pancreatic cancer risk, but he can’t get the resources he needs to prove anything, and I can’t remember his exact argument. More broadly: like all medications, semaglutide has benefits and risks, and you shouldn’t blindly take it after reading one blog article. Postscript 2: Is There A Way To Cheat The System To Get Semaglutide For Lower Cost? Health care is much like airline tickets: everyone pays a different price for everything and there’s usually a secret way to get what you want for much less money. Is this true of semaglutide? Pharma company Novo Nordisk offers a Savings Card that they say brings the price down to as low as $25 per month. I’m a little suspicious of this - pharma company offers are rarely as good as they sound - but I don’t notice any obvious tricks in this one and it should probably be your first bet. This startup claims that they can get insured people semaglutide for a $25/month copay “after their deductible is met” by negotiating with the insurance company very effectively. I can’t imagine how that works or what they have to negotiate with, but they seem pretty convinced, so I would welcome more information. Otherwise, you don’t have many great options. Although there are two older forms of semaglutide not FDA-approved for weight loss - Ozempic and Rybelsus - these are both more expensive, milligram per milligram, than Wegovy itself. Canada is also of no help. The usual Canadian pharmacies don’t seem to carry Wegovy, and charge about the same amount for Ozempic as American pharmacies do. This article in Drug Discovery Trends says that compounding pharmacies have been selling semaglutide for $300/month, less than a quarter of the sticker price. This is a bit confusing: compounding pharmacies are small local operations permitted to dispense unusual medications by mixing existing ones together in nonstandard ways. They’re arguing that they can legally dispense the semaglutide because they’re mixing it with vitamins, which, fine, but how are they getting it in the first place? Everyone else seems as confused as I am: "Nobody knows how [compounding pharmacies are] getting it," said Karl Nadolsky, an endocrinologist at Spectrum Health. "Who's making it? [The pharma company that makes it] Novo [Nordisk]'s not giving it to them. They're the ones with the rights to the molecule, so how is anybody getting semaglutide?" Has nobody asked compounding pharmacists about this? Do they have a conspiracy of silence? Does the FDA sometimes send their goons in to extract the information, but the compounding pharmacists compound sleeping gas / smoke grenades and vanish into the night? Anyway, the usual authorities warn you not to take compounded semaglutide under any circumstances, but they’re the same people who tell you never to buy drugs from a Canadian pharmacy because they might be adulterated. You can decide how much you want to trust them. Postscript 3: What About Europe And The Rest Of The World? Countries that are not the US usually negotiate with pharmaceutical companies over price. Because of some combination of “negotiation works” and “they are free-riding off Americans’ hard work”, they usually get much lower prices. What does semaglutide cost elsewhere? This is hard to find out because government health agencies sometimes keep their prices secret, plus Wegovy mostly isn’t available in other countries yet. The only information I could find was from Britain, which is in the process of making Wegovy available to patients. It looks like NHS will “restrict the expensive drug’s availability to very obese people attending specialist weight-loss clinics”, but that it might be possible to get it from private clinics for £199/month = £2400/year. Wegovy has been approved in the EU but doesn’t seem to have made it there yet. I can’t find any information about any other country. Non-weight-loss-indicated versions of semaglutide are available in many countries, but I wouldn’t expect their health care systems to be flexible about redirecting it for weight. Canadian regulators have approved Wegovy, but it doesn’t seem to be available there yet. I haven’t seen any evidence that Ozempic costs less in Canada than it does in the US, and I’m not sure why. Maybe the pharma companies have figured out that anything that happens in Canada gets imported into the US, and they’re playing hardball this time. I don’t know whether Canadians will be able to get it for cheaper than Americans or not. Postscript 4: Predictions (all predictions are conditional on no singularity or global catastrophe) 10 million Americans on semaglutide (or yet-to-be-approved equally good or superior alternatives) by 2030: 75%
Semaglutide is now as searched-for on Google as Prozac or Viagra. Even if this is a temporary Musk-related spike, even pre-Musk it was getting a little above half their level. But Google Trends doesn’t exactly track awareness; few people search for Prozac these days precisely because everyone already knows what it is. So all this tells us is that there’s a lot of buzz around semaglutide. Suppose for the sake of argument that 5% of obese people have heard of this drug. Step 2: Prescription Accessibility The FDA says Wegovy is indicated for obesity, defined as BMI ≥ 30, or for people with BMI ≥ 27 and certain medical conditions. Does that mean that if you have that BMI, your doctor will give you a prescription? I think most doctors will want patients to try diet and exercise first. My experience as a doctor is that most obese people have already considered diet and exercise. Sometimes if you have a very compelling reason and a very well-thought out plan you can get them to try again. But usually they are obese because diet and exercise are hard for them, or don’t work for them, or some other reason besides “they never thought of it”. Still, I hear lots of stories about patient-doctor fights here. I assume this will happen with Wegovy too. Every doctor will have their own threshold for what amount of “already tried diet and exercise” is enough to justify a Wegovy prescription, and sometimes patients won’t meet that threshold. The history of medicine includes the following story many times: there’s some condition that doctors recommend lifestyle changes for. Then an exciting new medication comes out that treats the condition effectively. Over a generation or so, doctors go from demanding the lifestyle change, to gesturing at the lifestyle change before prescribing the medication, to mostly just prescribing the medication. We saw this with cholesterol and statins, with hypertension and ACE inhibitors, with depression and SSRIs. You can form your own opinion on whether this is good or bad, but we’re probably in the very beginning of this process with obesity. Opinions will be all over the map for a while before the inevitable pharma company victory makes everyone agree that semaglutide is first-line therapy. …except that this time, Silicon Valley is short-circuiting the process with fly-by-night telemedicine companies that guarantee you’ll get the drugs you want. For example, NextMed charges $138/month ($99 first month only!) for a guaranteed GLP-1 agonist prescription, plus “support and messaging with expert doctors”. The DEA sometimes shuts these groups down when they start playing around with controlled substances (eg addictive drugs like Adderall), but Wegovy isn’t controlled, and the government probably doesn’t care that much here. These services guarantee that people with money will be able to circumvent conservative doctors and access a prescription. Only 75% of Americans have PCPs at all. If we assume half of them will eventually be able to get a Wegovy prescription from their doctor, that’s 37.5%. Step 3: Affordability Semaglutide costs $15,000/year. Well-off people like Elon Musk might be able to pay that out-of-pocket, but most people will probably need insurance coverage. Right now this is spotty. Medicare doesn’t cover obesity drugs. This isn’t a reaction to the threat of semaglutide-related cost explosions - they’re not that smart. I think Medicare laws were just written in the old days when people were less likely to think of obesity as a disease. Is it time for change? Some Congressmen have proposed a very noble-sounding law telling Medicare and Medicaid to start covering weight loss drugs. I‘m sure this is out of deep compassion for America’s obese population and not because it would make pharma companies one billion zillion dollars. One of the Congressmen even has the last name “Kind!” Some pharma lobbyist probably got a bonus for that one. Private insurers mostly have to cover whatever Medicare does, but they can choose whether or not to include extra non-Medicare-covered drugs. Some have chosen to cover semaglutide under some conditions. Others would prefer not to cover it, but can be scared into covering it by the magic words “medical necessity”. Overall I don’t understand the laws here beyond that maybe they’ll cover it and maybe they won’t. Here, too, it might be time for change. The New York Times is publishing articles trying to convince us that private insurances not covering semaglutide is an outrage. Here in the tiny gray text, I want to take a second to complain about this article. It notes that Wegovy (semaglutide for obesity) costs more per prescription than Ozempic (semaglutide for diabetes), and calls this “a gross inequity”, accusing Novo Nordisk of “charg[ing] people more for the same drug because of their obesity”. But the obesity prescription is higher dose than the diabetes prescription! Milligram per milligram, Wegovy costs *less* than Ozempic! A steelmanned version of the NYT might object - don’t most of the costs come from the intellectual property and not the manufacturing, so that dose shouldn’t matter? Yes, but if you made the obesity version cost too much less per milligram than the diabetes version, then diabetics would cheat the system by buying the obesity version and splitting it into smaller doses! Insurances that do cover it may require extra documentation that the patient has tried lots of diet and exercise, maybe including some official diet-and-exercise program like WeightWatchers. They might also want documentation that patients have tried cheaper earlier-generation weight loss drugs without success. Even when insurances do cover semaglutide, copays may be very high. I have a pretty minimal insurance and it looks like if I got semaglutide my copay would be about $500/month until I reach my out of pocket limit. Harsh. People with better insurances might get hit less hard, but I don’t think anyone will be picking this up for cheap. Let’s say only 5% of people who clear all previous hurdles can afford the drug. How Many People Get Semaglutide? 140 million obese Americans * 25% interested * 5% know of semaglutide’s existence * 37.5% can get prescriptions * 5% can afford it = 33,000, which is a pretty good match for the 50,000 estimated prescriptions. I didn’t even fudge the numbers to come out right, it just happened. The Coming Decade As a service to pharma investors, Morgan Stanley modeled the economic future of obesity medications over the next decade. Their headline result: semaglutide and various semaglutide-copycat-drugs will be a $30 billion market by 2030. That’s less than the $500 billion disaster I was afraid of! But still almost 10% of all US drug spending! Here are two core analyses from the report: The first analysis asks “what if doctors medicalized obesity as comprehensively as they’ve medicalized hypertension and high cholesterol?” That is: what if we put in a society-wide effort to get every obese person to a doctor, and after only a little diet and exercise, the doctor puts them on a medication? They find that the US obesity market would multiply by a factor of 25, to about $87 billion/year. The second analysis is a more realistic projection for the next decade. Two things stand out. First, the number of patients on Wegovy or related medications goes from an estimated 46,910 now (pretty close to my 50,000 estimate!) to 11.3 million in 2030. Second, the cost per prescription goes from $15,000/year to about $4,000 year. Let’s look at this second change in more detail. Right now semaglutide is literally in a class of its own for weight loss. But remember, it started as a GLP-1 agonist diabetes drug. And there are other GLP-1 agonists already in use for diabetes. Novo Nordisk’s competitor Eli Lilly owns a closely related molecule, tirzepatide (Mounjaro®). They’ve already done studies showing it also works very well for weight loss - if anything even better than semaglutide - and they’re expected to get FDA approval to market it as a weight loss medication next year. Although capitalism fans might expect the presence of two competing drugs to immediately drive down prices, this is mysteriously not how things work in health care and prices will probably stay the same in the short term. But several other companies are working on semaglutide-like drugs, some will be cheaper to produce than semaglutide, and Morgan Stanley expects that this stronger level of competition will eventually drive costs down to $350/month ($4,000/year) by 2030. “Mounjaro” sounds like the playful animal sidekick in a Disney movie. From a purely economic perspective, semaglutide costs the health system money (because it’s expensive) but also saves the health system money (because we don’t have to pay for obesity consequences like diabetes and heart attacks). Which effect wins out? According to the Institute for Clinical and Economic Review, benefits would outweigh costs if semaglutide cost less than about $8,000/year. Since it costs $15,000 year now, it’s not cost effective. But if Morgan Stanley’s model comes true and it costs $4,000/year in 2030, then it will be cost effective. So at some point, Medicare (and so insurance companies) may start covering it more out of self-interest. I can’t tell whether the model takes this into account or not. (there’s also a third-level effect where it costs the health system money again, because it prevents people from dying of obesity-related complications, and dead people stop needing expensive health care. I think health economists are supposed to ignore this level.) 11.3 million prescriptions at $4,000/year comes to $45 billion, but Morgan Stanley expects that not everyone will fill their prescriptions consistently or stay on the medication the same amount of time, leading to their $31 billion figure. Towards The Glorious Post-Obesity Transhuman Future The Morgan Stanley report shows that even the greediest pharma investors, openly plotting to medicalize obesity, can’t bring themselves to believe in more than 11 million US semaglutide patients by 2030. That’s less than 10% of the US obese population. Isn’t that kind of disappointing? We’ve got > 100 million people dealing with a condition that not only makes them unhealthy, but also causes them psychological distress, and makes lots of people low-grade disappointed in and repulsed by our society. And we’ve got an effective drug that treats the condition. And we’re going to use it on less than 10% of the people involved? In 2032, semaglutide goes off-patent. It will probably take a few years to sort out legal issues and ramp up generic production, but by the mid-2030s, its price will go way down. I don’t think there are technical barriers to getting it down as low as $10 - $100 per month. By then, maybe there will be even more exciting branded weight loss drugs for wealthy people to choose from. But at the very least, semaglutide itself should become much more widely available even to poor or uninsured patients. I’m not sure what will happen. Will there be an inflection point, where so many people use semaglutide that obesity becomes unusual again, and then the remaining obese people start using it just to fit in? Will obesity become an optional fashion statement, like shaving your head or getting a tattoo? Or will semaglutide end up disappointing us in some way, like so many promising drugs have before? I come at semaglutide from a transhumanist perspective. I want to hack genetics and biology until everyone is as tall as they want, as strong as they want, as smart as they want, and whatever gender they want. If you want wings, you should be able to have wings. And yes, part of this vision is everyone having the weight they want. I’m not sure this will happen, but for the first time I can see a clear path to how it might. Postscript 1: Should You Take Semaglutide? I can’t answer this, please ask your doctor. But I do want to add that there are potential side effects I haven’t mentioned in this post, including nausea, gastrointestinal problems, pancreatitis, and kidney problems. Semaglutide has been accused of slightly increasing risk of pancreatic and thyroid cancers. Studies have found trends in this direction, but these conditions are so rare that even over thousands of patients over many years, the increase hasn’t yet reached clear statistical significance. The current consensus position is that it may increase thyroid cancer by a tiny amount not relevant to most patients, and that it probably doesn’t increase pancreatic cancer. I think my father has looked over these data more and is less sure than other people about the lack of pancreatic cancer risk, but he can’t get the resources he needs to prove anything, and I can’t remember his exact argument. More broadly: like all medications, semaglutide has benefits and risks, and you shouldn’t blindly take it after reading one blog article. Postscript 2: Is There A Way To Cheat The System To Get Semaglutide For Lower Cost? Health care is much like airline tickets: everyone pays a different price for everything and there’s usually a secret way to get what you want for much less money. Is this true of semaglutide? Pharma company Novo Nordisk offers a Savings Card that they say brings the price down to as low as $25 per month. I’m a little suspicious of this - pharma company offers are rarely as good as they sound - but I don’t notice any obvious tricks in this one and it should probably be your first bet. This startup claims that they can get insured people semaglutide for a $25/month copay “after their deductible is met” by negotiating with the insurance company very effectively. I can’t imagine how that works or what they have to negotiate with, but they seem pretty convinced, so I would welcome more information. Otherwise, you don’t have many great options. Although there are two older forms of semaglutide not FDA-approved for weight loss - Ozempic and Rybelsus - these are both more expensive, milligram per milligram, than Wegovy itself. Canada is also of no help. The usual Canadian pharmacies don’t seem to carry Wegovy, and charge about the same amount for Ozempic as American pharmacies do. This article in Drug Discovery Trends says that compounding pharmacies have been selling semaglutide for $300/month, less than a quarter of the sticker price. This is a bit confusing: compounding pharmacies are small local operations permitted to dispense unusual medications by mixing existing ones together in nonstandard ways. They’re arguing that they can legally dispense the semaglutide because they’re mixing it with vitamins, which, fine, but how are they getting it in the first place? Everyone else seems as confused as I am: "Nobody knows how [compounding pharmacies are] getting it," said Karl Nadolsky, an endocrinologist at Spectrum Health. "Who's making it? [The pharma company that makes it] Novo [Nordisk]'s not giving it to them. They're the ones with the rights to the molecule, so how is anybody getting semaglutide?" Has nobody asked compounding pharmacists about this? Do they have a conspiracy of silence? Does the FDA sometimes send their goons in to extract the information, but the compounding pharmacists compound sleeping gas / smoke grenades and vanish into the night? Anyway, the usual authorities warn you not to take compounded semaglutide under any circumstances, but they’re the same people who tell you never to buy drugs from a Canadian pharmacy because they might be adulterated. You can decide how much you want to trust them. Postscript 3: What About Europe And The Rest Of The World? Countries that are not the US usually negotiate with pharmaceutical companies over price. Because of some combination of “negotiation works” and “they are free-riding off Americans’ hard work”, they usually get much lower prices. What does semaglutide cost elsewhere? This is hard to find out because government health agencies sometimes keep their prices secret, plus Wegovy mostly isn’t available in other countries yet. The only information I could find was from Britain, which is in the process of making Wegovy available to patients. It looks like NHS will “restrict the expensive drug’s availability to very obese people attending specialist weight-loss clinics”, but that it might be possible to get it from private clinics for £199/month = £2400/year. Wegovy has been approved in the EU but doesn’t seem to have made it there yet. I can’t find any information about any other country. Non-weight-loss-indicated versions of semaglutide are available in many countries, but I wouldn’t expect their health care systems to be flexible about redirecting it for weight. Canadian regulators have approved Wegovy, but it doesn’t seem to be available there yet. I haven’t seen any evidence that Ozempic costs less in Canada than it does in the US, and I’m not sure why. Maybe the pharma companies have figured out that anything that happens in Canada gets imported into the US, and they’re playing hardball this time. I don’t know whether Canadians will be able to get it for cheaper than Americans or not. Postscript 4: Predictions (all predictions are conditional on no singularity or global catastrophe) 10 million Americans on semaglutide (or yet-to-be-approved equally good or superior alternatives) by 2030: 75%
Last week I wrote The Media Very Rarely Lies. I argued that, although the media is often deceptive and misleading, it very rarely makes up facts. Instead, it focuses on the (true) facts it wants you to think about, and ignores other true facts that contradict them or add context. This is true of establishment media like the New York Times, but also of fringe media like Infowars. All of the “misinformation” out there about COVID, voter fraud, conspiracies, whatever - is mostly people saying true facts in out-of-context misleading ways.
https://www.nytimes.com/2001/12/20/world/nation-challenged-secret-sites-iraqi-tells-renovations-sites-for-chemical.html
Hello, my name is Samantha Hill. I am a 43-year-old political liberal from Chicago, Illinois. My interests include fighting for equal rights, reading The New York Times op-ed section, volunteering for progressive political campaigns, and playing guitar. I am passionate about combating climate change and ensuring that all people have access to affordable healthcare. In my free time I enjoy hiking, trying new ethnic foods and playing with my beagle, Tilly. If you had to choose, would you rather have... (A) A smaller government providing fewer services (B) A bigger government providing more servicesHello, my name is Tom Smith. I am a politically conservative man from Texas. I am an avid hunter and gun enthusiast. I am a Christian and regularly attend church. I am very patriotic and support the military. I am a small business owner that believes in limited government regulation. I am a family man with traditional values and I believe in preserving our American way of life. If you had to choose, would you rather have... (A) A smaller government providing fewer services (B) A bigger government providing more servicesYou can see the full list of ten thousand biographies here. In fact, you should definitely do this. They asked an AI - with no concept of what is or isn’t an offensive stereotype - to generate 5,000 liberal biographies and 5,000 conservative biographies. The result is a work of art. For example, the liberals are almost all women whose names radiate strong white college girl energy (plus a smattering of Latinas). In contrast, 80%+ of the conservatives are named either “John Smith” or “Tom Smith”, although I was also able to find “Tom Brady” and “Tom DeLay”. I want to put this on a space probe so aliens can one day find and decode it to learn about our society.
35: Matt Taibbi writes about Hamilton 68, supposedly a sophisticated group tracking Russian bot activity. The New York Times, MSNBC, and Politifact all wrote stories about Russian disinformation campaigns based on their research. Apparently new information reveals Hamilton 68 just sort of randomly declared normal human US conservative commentators “Russian bots” (along with a smattering of obvious Russian accounts like the Russia Today newspaper), tracked their activity to make a “Russian bot activity dashboard”, and hid this by refusing to release their list or explain their methodology. Seems bad.
In theory this also paves the way for human meat, though regulators might have other ideas. 2: Eight years ago I wrote an article about how the government should stop restricting doctors’ ability to prescribe suboxone, a useful medicine for opioid abuse. Last month, the government finally stopped the restrictions. Good for them! 3: Carl Sagan married three times. His first wife was legendary biologist Lynn Margulis, who discovered mitochondrial endosymbiosis, then went off the deep end and became an AIDS denialist and 9/11 truther. His second wife drew the Pioneer plaque. His third wife was one of the women who designed the Voyager golden record. 4: Claim: Chinese sources seem to back this up (and related BBC), but I’m skeptical: is this really the best way to satisfy a “must fight with medieval weapons” constraint? Why not crossbows? 5: Did you know: Alex Berenson, who runs the most popular anti-vaccine Substack, has had an unusual career: he used to be an investigative reporter for the New York Times, and also wrote a series of bestselling spy novels. 6: Less Wrong: I Converted Book 1 Of The Less Wrong Sequences Into A Zoomer-Readable Format. Apparently there’s a thing where Zoomers are supposedly more likely to learn a text if you overlay it on on a fast-paced video game, example here. 7: By this point we’ve probably all heard stories about people who win the lottery and then end up bankrupt and miserable after X months or years. I had always assumed this was limited to very poor people with no understanding of money. This forum post argues it’s not, and tells the story of a man who started out with $15 million and still ruined his life after winning $170 million more in the lottery. 8: Did you know: Exiliarch Mar-Zutra II was a 5th century Jewish leader who took advantage of the chaos caused by weird Zoroastrian communists to secede and turn the city of Al-Mada’in, Iraq into an independent Jewish state for seven years. 9: Why doesn’t the Supreme Court have vice-justices? 10: Steve Sailer (warning: unz.com, far-right site, some firewalls will flag or block it): why aren’t there more gay English soccer players? Thousands of current or recent English pro soccer players, the media is really interested in finding a gay one so they can run a “Historic First” article, and apparently they can’t. There are rumors that players are afraid to come out because of homophobia, but there are at least 2,000 retired soccer players and only one of them has come out as gay. “I’m increasingly sympathetic to [the] theory that whatever psychosocial traits make men highly interested in team sports make them highly heterosexual too”. Is this true of other countries and other sports? 11: Adam Tooze on the demographic background to Iran’s protests. Iran thought it was facing an overpopulation crisis in the 80s and tried some reforms to lower family size. The reforms worked overwhelmingly well, causing “the most dramatic transition ever recorded in demographic history”, from 6.5 to 2.5 children per woman in thirty years. Iran now has “lower maternal mortality than the US”, and an education system where “women in university outnumber males”. This kind of demography isn’t usually compatible with patriarchal religious institutions, and the Ayatollahs are aware of this; in a rare admission of error, Khameini said that “Government officials were wrong on this matter, and I, too, had a part. . . . May God and history forgive us.” Now they’re trying to increase average family size and put the genie back in the bottle; Hungary can tell them about the limits of that strategy. 12: What it looks like to be on shrooms: I haven’t used shrooms myself so cannot confirm or deny, but this is oddly compelling, and makes some things I’ve read about neuroscience of vision make more sense. I wonder if you could get HPPD from watching videos like this for too long. 13: Study: federal cancer funding is extraordinarily effective. Cancer research produces so many valuable treatments that it saves one DALY per $326 spent. For comparison, health systems usually consider an intervention good value-for-money if it saves at least one DALY per $50,000. By combing the Earth far and wide, effective altruists have tentatively found one or two opportunities in the poorest parts of Africa to save lives at $100/DALY, but these are extremely rare exceptions and I wouldn’t have expected anything in the US to be within an order of magnitude of that. Either this finding is fake, or we should all be donating to federal cancer research instead of whatever else we’re doing. 14: Yet another person building a vast theory of human interaction off of the characters in The Office. This one is pretty good, also name-drops Bobos In Paradise. I’m still surprised this is such a common thing. 15: Marginal Revolution: FDA Deregulation Increases Safety And Innovation And Reduces Prices. Study looks at what happens when the FDA reclassifies medical devices from a highly-regulated to a less-highly-regulated category; in general, those devices get better, cheaper, and there are somewhere between similar and fewer deaths/injuries related to those devices. Why would safety increase? The author suggests that regulation is a defense against lawsuits (“Your Honor, the FDA agreed to approve our device, so it can’t have been bad!”), and removing that defense makes companies more lawsuit-conscious and careful; Alex Tabarrok suggests a bigger effect may be allowing more innovation towards safer versions. 16: Ozy writes about Interesting People Of History: Charles Williams (ie the other member of the Inklings) 17: Did you know: the Congressman who founded the House Committee On Un-American Activities was, in fact, a paid Soviet spy (tweet, Wiki article). This actually makes sense; he originally started HUAC to root out fascists, and it only got turned against communists later on. “There has been a push to rename the street [currently named after the Soviet spy], but as of 2018 it has been unsuccessful.” 18: Idle Words: Why Not Mars? Surprisingly strong argument for why sending humans to Mars is harder than people think, of minimal scientific value, and likely to contaminate all future searches for microbial life and ruin our chance to study the topic. Concludes that we should abandon the allure of human space travel and just send probes everywhere. This makes short-term sense, but I wonder what this author’s vision of the future is - do we just stay on Earth forever? If not, don’t we have to start trying to do the hard thing at some point? (I don’t care about this because I assume AI will will flip the gameboard one way or another, but Ceglowski is a noted singularity skeptic and should probably have opinions about long-term things). 19: Metacelsus and Razib on epigenetics. Stop using it to claim there’s “intergenerational trauma”! 20: Tafl games are a family of European games, played in areas as diverse as Iceland, Ireland, Britain, and Denmark, probably sharing descent from a now-lost board game of ancient Rome. One of them, Hnetafl, was the chief board game of the Vikings and is affectionately called “Viking chess”. The one we actually know the rules for is the Saami version, Tablut, which survived long enough for Linnaeus (the taxonomy guy!) to write down the rules. 21: Shot: Chaser: (source) 22: Related: the very center of GPT’s embedding space contains a few unusual tokens including the string “SolidGoldMagikarp”. GPT displays anomalous behavior if these tokens are inserted in a query; for example, it treats “SolidGoldMagikarp” as the word “distribute”. ChatGPT is pretty advanced and fails semi-gracefully here; GPT-2’s reaction to these tokens is more disturbing: (source: Less Wrong) Further investigation determined that many of these tokens are the screen names of a group of Redditors who attempted to count to infinity. The most likely explanation, according to the discoverers, is that these names were in GPT’s tokenization data, but not its training data (maybe they were especially common in the tokenization data because they made thousands of posts with numbers in them, but didn’t make it into the training data because their posts had no content?) - that leaves them existing without content, and GPT tries to round them off to some other “nearby” token (by incomprehensible AI standards of nearbyness). Congrats to the SERI-MATS AI alignment researchers who found all of this; maybe this makes it 0.0001% less likely that the AI which controls the nuclear arsenal in twenty years will have equally inexplicable behavior. 23: More language model news: LLM that understands and can explain images
An advertisement for the author’s hedge fund Michael Gibson’s memoir Paper Belt On Fire succeeds on all counts. The year was 2007. Gibson had just dropped out of Oxford (grad student, philosophy), and applied for a job with the CIA. His secret reason: when he was one year old, his father had admitted to his mother that he was a spy and might be in danger. Before he could tell her anything else, he was found dead, apparently of a heart attack. He thought maybe if he worked at the CIA, he would have access to more information about what happened. The CIA evaluated him (along with a telephone interview, an “IQ test, a personality test, a statement of values, [and] a set of essay questions”) and rejected him. Gibson got a job as an editorial assistant at a tech magazine and blogged on the side. Some of his blog posts came to the attention of Peter Thiel, who offered him a job at his hedge fund. Wasn’t it a bit bold to offer an Oxford philosopher a hedge fund job? Yes, the book mentions how brave and radical and unconventional Thiel’s hiring policies are about twice per paragraph. For example: The media consistently gets Peter wrong . . .The Atlantic’s George Packer wrote . . . that Peter’s hedge fund had the reputation of being a “Thiel cult” that was “staffed by young libertarian brains who were in awe of their boss, emulating his work habits, chess-playing, and aversion to sports.” Packer is a great writer, but in this he was dead wrong, as anyone actually working on the desk knew. Sure, Patrick “the Wolf Man” Wolff was technically a chess grandmaster, ranked higher than Peter, but hardly anyone else ever played. More importantly, the Wolf Man was a diehard Krugman Keynesian. Woersching was a lefty, too, an ardent fan of the egalitarian philosophy of John Rawls. And Josh, he was a dirt-road California Democrat who was a downhill ski junkie […] In truth, Peter didn’t hire just libertarians. He hired scapegoats who’d survived a mob. People who felt comfortable being a minority of one. Thiel in no way selects employees who agree with all of his controversial libertarian opinions. But, by total coincidence, Michael Gibson does agree with all of Peter Thiel’s controversial libertarian opinions. He writes about Cardwell’s Law; historian Donald Cardwell noted that no country remains on the cutting edge for long. During the early Renaissance, Italy was where it was at; a century later, it was Spain and Holland; later still, Britain and Germany, and now new discoveries and businesses come disproportionately from the United States. Why? Gibson and Thiel think that innovation is a rare and fragile plant, which thrives only in the hidden cracks between power structures. Established structures either stamp it out as a threat, or rent-seek off of it so hard that they bleed it dry. Wherever it succeeds, it has succeeded through weird quirks that prevent fat cats from parasitizing it to death. Hong Kong’s economic miracle was during the administration of John Cowperthwaite, an eccentric British libertarian who refused to collect economic statistics because he thought they would make it too easy for meddlers to extract value. America’s economic miracle happened because of a vast frontier - which not only provided freedom for westerners, but served as a BATNA for easterners, preventing their own institutions from sucking them too dry. Now the frontier has closed. New York City recently abandoned its attempt to build a light rail line to the airport: after reaching a $2.4 billion price tag and spending eight years in the planning phase, the government realized it wouldn't be able to overcome all the legal hurdles necessary to grant itself permission. The San Francisco Chronicle reported that it requires 87 permits, two to three years, and $500,000 to get permission to build houses in SF - and your plan might still get shot down because a planning commissioner thinks its glass windows are “a statement of class privilege”. The cracks have shut; the rare fragile plant has been shredded by a combine harvester. Gibson, like Thiel, is a believer in the Great Stagnation - the theory that we’re already reaping the consequences of our newly parasitic society. The early 20th century gave us cars, airplanes, electricity, and penicillin; the early 21st has so far given us some truly excellent social media sites but not much else. Innovation in the world of bits - unbound by geography, comparatively hard to regulate or extort - has sort of continued; innovation in the world of atoms has ground to a halt. And Gibson, like Thiel, talks like a man on a mission. What is good in man thrives only in a few tiny cracks, easily found and destroyed. The last crack was closed within living memory, but its legend hasn’t completely died; the few people who managed to pick up a little of its lore are racing against time to open a new crack before it is entirely forgotten and their project is left to the vicissitudes of history. The cover of “Paper Belt On Fire” goes hard. And yes, the “money” part is a reference to Bitcoin. Gibson’s heart was originally in charter cities - asking some government to open a tiny controlled crack in a sliver of its territory, promising it more meat in the end if it lets its victims grow fat and healthy than if it strangled them in the cradle. But for whatever reason they thought the time wasn’t ripe (the right time, apparently, would be 2019). Instead, Thiel asked Gibson to work on what would become the Thiel Fellowship. He teamed up with Danielle Strachman, a dangerously-hippie-adjacent burnt-out former charter school principal. Their plan was simple: offer talented kids $100,000 to drop out of school and do something exciting in the real world (usually start a company). Paper Belt spends long pages on the hate they got. Larry Summers called it “the single most misdirected bit of philanthropy this decade”. Journalist Jacob Weisberg said anyone who accepted the Fellowship would “halt their intellectual development at the onset of adulthood, maintaining a narrow-minded focus on getting rich as young as possible and thereby avoid the siren lure of helping others or pursuing knowledge for its own sake” (this was before journalists decided that helping others was also evil). Others focused on how there was no way any of these young people would possibly succeed or make money - when the first batch of Thiel fellows failed to revolutionize the world within one year, journalist Vivek Wadhwa wrote Billionaire’s Failed Education Experiment Proves There’s No Shortcut To Success. In fact (slightly conflating the part with the Fellowship with its successor fund): The press . . . hated us. In a 2016 New York Times op-ed, science journalist and author Tom Clynes claimed that “radical innovation has yet to emerge” from anything related to the Thiel Fellowship, and that “the biggest hits have been the most pedestrian.” Antonio Garcia Martinez, the author of the Silicon Valley memoir Chaos Monkeys, spewed forth his bile for us on social media: “For fans of ironic stupidity, Silicon Valley is a never-ending feast”, he wrote on Facebook. He went on to explain, with great vulgarity, why our fund would fail by backing young dropouts. My favorite . . . has to be the challenge issued by Scott Galloway, a professor and bloviator in marketing from NYU’s business school . . . who told Business Insider that if he picked ten smart recent graduates from his alma mater, the University of California at Berkeley, they would outperform any ten dropouts we worked with on some dimension of success related to income or startup formation. Of course he wouldn’t have written the book if any of these people had been right. I can’t find a list of all Thiel fellows, but there are ~20 per year and it’s been running about 12 years, so maybe 200 - 250? At least eight have founded companies valued at over a billion dollars, and others have become impressive philanthropists, activists, and scientists. Pretty good success rate. Gibson argues it’s not about the money, it’s about the mission. We’ve told young people they can’t succeed without the stamp of approval from big institutions. In order to get that stamp, they sacrifice their childhood on the altar of doing things that look nice to admissions officials, then go deep into debt to pay ruinous tuitions. All to waste four years of their lives listening to some professor drone on about post-colonial gender relations in Harry Potter so they can satisfy their gen ed requirement so they can learn the stuff they want to learn so they can get hired by McKinsey so that one day they can be cool and important enough to make a difference in the world. Why not tell young people they can just make the difference right now, without doing any of that? It’s not about the money - but when your graduates are routinely founding billion dollar companies, you’d be crazy to keep it that way. After a few years, Gibson and Strachman noticed the billion-dollar-bill lying on the ground, left the Thiel Fellowship, and started a new VC fund, 1517 (named after the year Martin Luther did some institution-challenging of his own). Their business plan was to do roughly the same thing as the Thiel Fellowship - only this time, invest in the companies beforehand (the parting with Thiel seems to have been amicable; he invested $4 million). So Gibson adopted the life of a venture capitalist. He talks frankly about the difficulties. For example, in one case he found someone nobody else believed in, gave them enough money to keep going, and helped them start their company in exchange for them giving Gibson a certain stake. After the company succeeded, Gibson accuses bigger VC firm Sequoia Capital of convincing the founder to kick him out, and stealing his stake. He says that in the world of VCs it’s poison to sue founders for any reason, so nobody can enforce contracts, so if your founders defect to a different VC for more money, there’s nothing you can do (this is not legal advice). Also, “please give me millions of dollars so I can invest it in college dropouts” is a tough sale for everyone except Peter Thiel. Still, he got a bit of money and tried his best. He takes as his - would it be insensitive to say “role model”? - John Walker Lindh, the American who defected to the Taliban (and who he apparently looked like). Probably it depends on the angle or something. Lindh was the only American to find Osama bin Laden in the early 2000s - he went to lots of jihadi training camps in the process of learning how to jihad, and Osama happened to be at one of them. The lesson, Walker says, is that if you want to find people who are hard to find, you need to steep yourself in their culture, truly understand them, become one with them. Good founders are hard to find. But he and Strachman went to dozens of dingy college dorms, math competitions, group houses, and hackathons, looking for people with the right sort of talent. After pooh-poohing IQ (“Marilyn vos Savant is listed as having the highest recorded IQ, and what does she do? She writes a column for a Sunday supplement in the newspaper”) he lists some of his own preferred metrics for judging would-be Thiel fellows and founders: Polytropon - a famously untranslatable Greek word (“of-many-turns”? “always-has-a-trick-up-his-sleeve” “clever bastard”?) used to describe Odysseus. Edge control - willingness to constantly surf the boundary between order and disorder Crawl-walk-run - ability to scale from a tiny startup to a big company. …and several others, including “tensive brilliance” and “Friday night Dyson sphere”. He and Danielle searched the country for people with these qualities, annoying colleges (he was banned from MIT after showing up too often to convince their students to drop out) and doing various stunts (on October 31 2017, the 500th anniversary of Luther’s theses, he nailed a list of anti-formal-education theses to the doors of the admin buildings of top colleges (“Our commercial printer had misunderstood our request and printed them on seven-foot-long scrolls. They were ridiculous . . . but it turned out for the best.”) At one point, he negotiated with a brilliant 21 year old who may have discovered a transformative diabetes therapeutic, but the hidebound conformist novelty-hating establishment refused to work with him just because he liked the Marvel Cinemat - okay, fine, he may have legally changed his name to “Tony Stark”. Still, Gibson saw past his eccentricities, helped him start his company, and gave him sage advice (he should introduce himself to other investors as “Anthony”). Skip through several more chapters of everyone hating Gibson and telling him he was wrong and refusing to give him money and cheating him out of the money he already had, and the payoff is Luminar. One of the dropouts they cultivated founded a beyond-cutting-edge lasers-for-self-driving-cars company which went public at $3 billion. 1517 made $200 million from the deal - it sounds like they had only ever raised about $25 million, so their investors must have octupled their money on that company alone. Everyone involved is now very rich, and Gibson considers his anti-education thesis on the way to being proven. The book ends with a newly-resourced Gibson continuing his quest to figure out whether and why the CIA killed his father, but it’s slow going. If any of you know a guy named Albert van Dam in Amsterdam, or how to convince Swiss banks to reveal secret account information, get in touch with him. II. A common pattern: I assert something. Everyone yells at me and tells me I’m wrong and stupid, sometimes in very colorful language. I wait, time proves me right, and I write an essay gloating educating people about this. The median comment is “of course this is true, nobody ever denied this was true, why are you wasting our time with something obvious?” I hate this and I try to avoid doing it to other people. This is too bad, because I’m tempted to say: obviously talented dropouts can start good companies. We’ve known this at least since Bill Gates dropped out of Harvard in 1975 to start Microsoft. But also, obviously they can. Brilliant and driven people can succeed whether they get a college education or not. If Bill Gates had stayed an extra two years at Harvard, he probably would have taken a few more advanced math classes not really related to programming software or running a company. So why should we even have as a hypothesis that he couldn’t start Microsoft successfully without doing that? Still, Gibson adequately proves that lots of people hated him and were sure he would fail. Either we should read this backwards - learn that there was once a time when pro-college messages were even stronger than now, so strong that people thought it was literally impossible to succeed without every single day of a four-year college application - or the critics were trying to get at something deeper they were bad at expressing. For example: what, exactly, is Gibson’s alternative to the education system? The back-of-book-blurb says Paper Belt On Fire is about “how higher education and other institutions must evolve to meet the dire challenges of tomorrow” - but evolve how? What exactly has been proven here? A few of the very brightest young people, hand-picked by an expert young-person-picker and given $100K, can become billionaires or make great discoveries without a college degree. What are the implications? Suppose you are an average college student with an average level of talent and motivation. Should you drop out and try to create a company for Peter Thiel? Based on how many average-talent people Thiel rejects, even he doesn’t think you should do that. And if you don’t have a good answer to this question - the one relevant to 99.9% of education system inmates - have you really launched a challenge to the educational system? Gibson doesn’t address this question, but I predict he would admit that, fine, he doesn’t have an alternative to the education system in the sense of “educate people this way rather than that way”. He just wants less formal education, and has proven this will work fine. True, he’s only proven it for a tiny subset of ultra-talented people. But “billionaire tech founder” is a hard job - if it wasn’t, more people would do it and reap the $1 billion reward. Proving that people can become billionaire tech founders without college degrees implicitly suggests they can be successful middle managers or budget analysts without college degrees. So the sort of companies that need middle managers and budget analysts should also consider hiring people without degrees, and the sorts of average-level-of-talent-and-motivation people who want these jobs should consider skipping college. Would this work? Probably. It worked in the early 1900s, when only 5-10% of Americans had college degrees but the country seemed about as dynamic and successful as it does now. It worked for people like George Washington, Abraham Lincoln, and Thomas Edison, none of whom went to college. It works in other countries - for example in the UK where young doctors skip undergrad and go straight to medical school, and whose patients get about the same outcomes as in the US. It works for people with impractical degrees like philosophy, who are constantly getting jobs in (and doing well in) fields that don’t require you to compare Locke vs. Leibniz’s perspective on a priori truths. So this would work if everyone agreed to do it at once, which they won’t. The way college gets you is adverse selection. Suppose that tomorrow, you - a smart and hard-working person who could easily get a college degree - decline to do so, because you appreciate Peter Thiel and Michael Gibson’s anti-institutional perspective. The pool of people without college degrees is now, to a first approximation: 200 million people who weren’t smart to get in, rich enough to afford it, or motivated enough to finish.
Tenure is the "weird path dependence due to historical circumstances" thing. Probably no one would set up the system the way it is today if one were starting from scratch. Tenure worked somewhat okay when lifespans were shorter and mandatory retirement hadn't been struck down the Supreme Court (one old article: https://www.nytimes.com/1994/06/15/us/new-law-against-age-bias-on-campus-clogs-academic-pipeline-critics-say.html).
Another thing we learn as American teenagers: it’s rarely as bad as all that. The news tells us of murders, riots, mass shootings, bigotry, greedy evil corporations, the hollowing out of the middle class. Eventually we learn that outrage sells, and “if it bleeds it leads”. All of these things are real problems but probably not so much as Channel 7 or the New York Times would like you to believe.
I found Unspeakable Conversations, by Harriet McBryde Johnson, useful for getting insight on the Social Model from the perspective of one of its advocates. https://www.nytimes.com/2003/02/16/magazine/unspeakable-conversations.html
The New York Times has an article on “dating docs”. These are a local phenomenon - I think an ex of mine might have been Patient Zero. I don’t begrudge the Times for writing about them. I’m just surprised they’re considered an interesting phenomenon. What could be more obvious than making sure potential dates know what you’re like?1
5: The New York Times recently published an article about the Manifest prediction market conference. I think it’s overall very good, and appreciate the care that the reporter put in to understanding the ideas (plus the frankly majestic picture of the Manifold co-founders). I do want to correct one paragraph, though:
The New York Times says he got the idea for the bill after:
The New York Times discusses how 327 individual shoplifters with 20+ arrests each are responsible for a third of the shoplifting in New York City!
We previously predicted a similar increase in incarceration would lead to an 80% decrease in crime in the US, but El Salvador got a 95% decrease in crime. Why did they do so much better than our prediction? I think because they started with half our incarceration rate and ten times our murder rate. When you’re starting from someplace terrible, without any of the low-hanging fruit picked, it’s easy to make progress! I can’t find good statistics on other crimes like theft, but the crappy statistics I find say it hasn’t budged (1, 2). Why not? Either my statistics are bad, or the gangs that the government cracked down on weren’t in the theft business.4 Incapacitation Fine, so despite power laws there’s no way to easily solve crime just by imprisoning a small number of people. How much bang for the buck do we get by incapacitating criminals? You would think this would be easy to figure out: just determine how many crimes the marginal prisoner commits per year. Then that’s how many crimes incapacitation prevents per year. But although it’s easy to see how many times the marginal prisoner has been arrested, most crimes don’t result in arrest. How do you know how many crimes they really committed? Some bold scientists have tried asking them - giving prisoners surveys about their criminal histories - but obviously these should be greeted with heavy skepticism. The method criminologists have settled on is to wait for big shocks to incarceration - big enough to affect the general crime rate - then see how much the crime rate goes up or down. The best study here is probably Levitt 1996 (you may know Steven Levitt from Freakonomics). In the 1970s, US prisons were overcrowded. The ACLU argued the overcrowding was a rights violation - a form of “cruel and unusual punishment” - and sued a dozen states. They won all their lawsuits, and judges in all states said the government had to free prisoners until prison crowding returned to a non-cruel, usual level. So at a slightly different time in each state, many prisoners got released all at once. By examining the effects of this sudden release on the crime rate, we can determine how much crime the incarceration of those prisoners was preventing. Levitt does a lot of fancy statistics, and Roodman reanalyzes with even more fancy statistics, but the good news is they both agree and get numbers somewhat contrary to Roodman’s biases, which make me trust them more. Each year of imprisoning the type of prisoner who got released under the ACLU lawsuits prevented 6 property crimes and 1 violent crime. This suggests the average criminal commits ~7 crimes per year, which I think matches well with the data above showing that the median prisoner has 10 past arrests and some have 30+. Other studies on incapacitation, mostly taken from Roodman, that I trust less than Levitt: Owens (2009) investigated a Maryland law that caused some criminals to get released early. They found a crime increase corresponding to about 3 crimes per prisoner per year. This is lower than Levitt’s estimate of 7, but crime rates went down in general between Levitt’s study period (the 70s) and Owens’ (the 2000s), so they might both be right.